# GLP-1-receptoragonisten verlagen nierkankerrisico na metabole bariatrische chirurgie

*geplaatst 2026-09-02 · Hartfalen · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · doi 10.1093/ndt/gfag197 · https://hartvaat.nl/2026/08/26/glp-1-receptoragonisten-verlagen-nierkankerrisico-na-metabole-bariatrische-chiru/*

In een retrospectieve TriNetX-cohortstudie bij volwassenen met type 2 diabetes en overgewicht of obesitas na metabole bariatrische chirurgie werd het nierkankerrisico vergeleken tussen patiënten die startten met een GLP-1-receptoragonist en die met metformine, insuline, SGLT2-remmers of sulfonyleureum. Na vijf jaar was GLP-1-RA-gebruik geassocieerd met een lager incident nierkankerrisico ten opzichte van alle vergelijkers, met absolute risicoverschillen van -0,18% tot -0,22%. Deze consistente bevindingen suggereren een mogelijk oncologisch veiligheidsprofiel en extra voordelen van GLP-1-RA's naast glycemieregeling, wat relevant kan zijn bij de keuze van glucoseverlagende therapie in deze specifieke patiëntengroep.

## English: GLP-1 receptor agonists are associated with lower kidney cancer risk after metabolic bariatric surgery.

In a retrospective TriNetX cohort of adults with type 2 diabetes and obesity or overweight status following metabolic bariatric surgery, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were compared with metformin, insulin, SGLT2 inhibitors, or sulfonylureas. Over five years, GLP-1 RA initiation was associated with a lower incidence of kidney cancer across all comparators, with absolute risk differences ranging from -0.18% to -0.22%. These findings, consistent across sensitivity analyses, suggest an additional oncologic safety signal for GLP-1 RAs beyond their established cardiometabolic benefits, which may inform therapeutic selection in post-bariatric patients.

## Abstract (original, from the publication)

BACKGROUND: Kidney cancer (KC) is an obesity-related malignancy with rising incidence. Although metabolic and bariatric surgery (MBS) reduces the risk of some obesity-related cancers, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) has increased after MBS; however, their association with KC risk remains unclear. We aimed to evaluate whether initiation of GLP-1 RA, compared with other glucose-lowering agents, is associated with KC among adults with prior MBS and type 2 diabetes (T2D), and overweight, or obesity. METHODS: We conducted a retrospective cohort study using TriNetX, applying an active-comparator, new-user target trial emulation framework. Adults (≥18 years) with T2D, obesity/overweight and prior MBS (2006-2025) were included, excluding those with prior cancer or type 1 diabetes. GLP-1 RA initiation was compared with metformin, insulin, sodium-glucose cotransporter 2 inhibitors (SGLT2i), or sulfonylureas. Time zero was the first post-MBS prescription after a 365-day washout. Propensity score matching (1:1) balanced baseline characteristics. The outcome was incident KC (ICD-10 C64, C65). Risk differences (RDs), and hazard ratios were estimated over 5 years. RESULTS: After matching, 16 768 GLP-1-metformin, 25 025 GLP-1-insulin, 8 613 GLP-1-SGLT2i, and 7 029 GLP-1-sulfonylurea pairs were included. GLP-1 RA initiation was associated with lower 5-year KC risk vs metformin (RD -0.18%; 95% CI -0.27 to -0.09), insulin (-0.22%; -0.30 to -0.15), SGLT2i (-0.19%; -0.34 to -0.04), and sulfonylureas (-0.20%; -0.37 to -0.03). Results were consistent across sensitivity analyses. CONCLUSIONS: Among post-MBS patients, GLP-1 RA initiation was associated with lower KC risk vs other therapies, supporting potential oncologic safety and benefits beyond glycemic control.

Auteurs: Jesús Gibran Hernández-Pérez, Omer Abdelgadir, Mohanad Albayyaa, Deepali K Ernest, Jing Chen, Stacia M DeSantis, Arthur S Hong, Lindsay G Cowell, Jaime P Almandoz, Sarah E Messiah, David S Lopez

---
Bron: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, https://doi.org/10.1093/ndt/gfag197. Bijgewerkt 2026-08-27T01:09:34Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.